Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to 0.54%.

  • Allogene Therapeutics' Return on Capital Employed fell 300.0% to 0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.49% for FY2024, which is 200.0% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Return on Capital Employed stood at 0.54%, which was down 300.0% from 0.56% recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Return on Capital Employed high stood at 0.18% for Q4 2021, and its period low was 0.56% during Q2 2025.
  • In the last 5 years, Allogene Therapeutics' Return on Capital Employed had a median value of 0.49% in 2023 and averaged 0.4%.
  • In the last 5 years, Allogene Therapeutics' Return on Capital Employed surged by 1300bps in 2021 and then plummeted by -2600bps in 2023.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Return on Capital Employed stood at 0.18% in 2021, then crashed by -135bps to 0.42% in 2022, then dropped by -23bps to 0.51% in 2023, then fell by 0bps to 0.51% in 2024, then fell by -5bps to 0.54% in 2025.
  • Its Return on Capital Employed was 0.54% in Q3 2025, compared to 0.56% in Q2 2025 and 0.54% in Q1 2025.